FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors - FDA Press Releases

The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs).

from Food and Drug Administration--Press Releases http://ift.tt/1RO595j
via IFTTT